SCHEMBL80987

SCHEMBL80987

Fc1ccc(I)c(F)c1F

nearest known ligand 0.40

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.40
CES1 P23141 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31070217 1.00 CES2 (0.40) CES2CES1
SCHEMBL1425995 0.87 NOTUM (0.31)
SCHEMBL29559941 0.87 NOTUM (0.31)
SCHEMBL45430 0.79 CES2 (0.53) CES2CES1
SCHEMBL29489580 0.79 CES2 (0.53) CES2CES1
SCHEMBL18709780 0.77 NOTUM (0.43) CES2CES1
Ammonia Solution, Strong SCHEMBL3047305 0.75 CES2 (0.50) CES2CES1
SCHEMBL11355080 0.75 CES2 (0.50) CES2CES1
SCHEMBL3975406 0.75 CES2 (0.50) CES2CES1
SCHEMBL23486898 0.75 NOTUM (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119264026-A Method for synthesizing cyclic sulfonamide and sulfonyl olefin by mechanical light excitation 西北大学 2025-01-07 CN claimed
EP-1362860-B1 Method for producing tetrakis (fluoraryl)borate magnesium compound NIPPON CATALYTIC CHEM IND (JP) 2010-09-15 EP claimed
US-7205441-B2 Method for producing tetrakis (fluoroaryl) borate-magnesium compound NIPPON SHOKUBAI CO., LTD. (JP) 2007-04-17 US claimed
US-20030216598-A1 Method for producing tetrakis ( fluoroaryl) borate-magnesium compound NIPPON SHOKUBAI CO., LTD. (JP) 2003-11-20 US claimed
EP-1362860-A1 Method for producing tetrakis (fluoroaryl) borate magnesium compound Nippon Shokubai Co., Ltd. (JP) 2003-11-19 EP claimed
EP-3667751-B1 PASSIVATION OF METAL HALIDE PEROVSKITES UNIV OXFORD INNOVATION LTD (GB) 2026-03-11 EP disclosed
US-12509987-B2 Continuous characterization and communication of chemical tracer Patina IP LLC (US) 2025-12-30 US disclosed
US-12288825-B2 Photovoltaic device comprising a metal halide perovskite and a passivating agent OXFORD PHOTOVOLTAICS LIMITED (GB) 2025-04-29 US disclosed
CN-119264026-A Method for synthesizing cyclic sulfonamide and sulfonyl olefin by mechanical light excitation 西北大学 2025-01-07 CN disclosed
WO-2024058815-A1 CONTINUOUS CHARACTERIZATION AND COMMUNICATION OF CHEMICAL TRACER Patina IP LLC (US) 2024-03-21 WO disclosed
US-11799039-B2 Photovoltaic device comprising a metal halide perovskite and a passivating agent OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-10-24 US disclosed
US-20230296018-A1 CONTINUOUS CHARACTERIZATION AND COMMUNICATION OF CHEMICAL TRACER Patina LLC (US) 2023-09-21 US disclosed
US-6235222-B1 REACTING, IN SOLVENT CONTAINING CHAIN ETHER SOLVENT, HYDROCARBON MAGNESIUM HALIDE WITH FLUOROARYL HALIDE NIPPON SHOKUBAI CO., LTD. (JP) 2001-05-22 US disclosed
EP-1061112-A1 ORGANIC ELECTROLUMINESCENT ELEMENT IDEMITSU KOSAN COMPANY LIMITED (JP) 2000-12-20 EP disclosed
EP-0995753-A2 Method for manufacturing fluoroaryl magnesium halide Nippon Shokubai Co., Ltd. (JP) 2000-04-26 EP disclosed
CN-1146159-A X-ray contrast compositions containing cellulose derivatives NYCOMED IMAGING AS (NO) 1997-03-26 CN disclosed
US-5213710-A Benzene derivatives and a liquid-crystalline medium MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1993-05-25 US disclosed
EP-0109606-B1 PROCESS FOR THE FORMYLATION OF ARYL HALIDES BAYER AG (DE) 1986-01-22 EP disclosed
US-4536344-A USING A PHOSPINE OR PHOSPHITE BAYER AKTIENGESELLSCHAFT (DE) 1985-08-20 US disclosed
EP-0109606-A1 Process for the formylation of aryl halides BAYER AG (DE) 1984-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216598-A1 Method for producing tetrakis ( fluoroaryl) borate-magnesium compound KRAS, MGAM, CA3 CES2 3957/4885CES1 4605/4885
US-12509987-B2 Continuous characterization and communication of chemical tracer EXOSC10, CD69, FABP3 CES2 2569/4885CES1 3128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.